Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Delaying Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis

NCT02430532 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT02430532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02430532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Delaying Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Terminated
Start date
May 31, 2015
Completion date
January 31, 2016
Enrollment
58 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, secondary progressive